Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

GSK stops two Phase 3 studies for novel antibiotic gepotidacin stopped early

By Brian Buntz | November 3, 2022

GSKGSK (LSE/NYSE:GSK) has announced that it would stop enrolling the pivotal EAGLE-2 and EAGLE-3 studies of the antibiotic gepotidacin based on advice from the independent data monitoring committee.

Gepotidacin is a topoisomerase type II inhibitor.

The EAGLE-2 and EAGLE-3 trials met the primary efficacy endpoint related to combined clinical and microbiological resolution. The EAGLE-2 and EAGLE-3 studies, involving data from more than 3,000 patients, sought to establish non-inferiority to nitrofurantoin for uncomplicated urinary tract infections (uUTIs).

EAGLE-2 and EAGLE-3 provided a test-of-cure (TOC) visit for gepotidacin compared with the traditional antibiotic nitrofurantoin in patients with a uUTI. Patients in the study were confirmed to have a uropathogen sensitive to nitrofurantoin. The data monitoring committee did not note any safety concerns.

GSK is gearing up a New Drug Application for gepotidacin, which it intends to file in the first half of 2023.

If approved, gepotidacin stands to be the first novel oral antibiotic for uncomplicated urinary tract infections in more than 20 years.

Uncomplicated urinary tract infections are exceptionally common, affecting more than half of women at some point in their lifetime. More than one quarter of women have recurrent uUTIs.

The most common cause of uUTI is Escherichia coli (e. coli) bacteria, which is becoming more resistant to current antibiotics.

“With the number of uUTIs caused by resistance bacteria increasing, new antibiotic treatments are necessary,” said Chris Corsico, SVP, Development, GSK, in a news release. “The IDMC’s recommendation to stop the EAGLE-2 and 3 trials early for efficacy provides GSK with the opportunity to engage regulatory authorities as we work together to bring a new class of antibiotics to patients with uUTIs.”

GSK intends to submit the collective data from the two studies in a peer-reviewed journal in 2023. It also plans on presenting the data at a scientific conference.

In all, gepotidacin has been the subject of roughly 20 clinical trials.

The company’s shares fell 0.82% to $32.85 in afternoon trading.


Filed Under: Obstetrics & gynecology
Tagged With: gepotidacin, GSK
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Endometriosis: An immune disease
Biomimetic digital twin ecosystem process tailored for the analysis.
Study combines biomimetic AI, digital twins and multiomics to unveil potential genetic drivers of endometriosis
positive pregnancy test in the hands of a girl close-up
The rise of ‘Ozempic babies’ and the uncharted territory of semaglutide in pregnancy
Mid-section portrait of unrecognizable woman during last months of pregnancy holding her big belly gently standing against wall in blue room
A J&J veteran highlights listening to address overlooked maternal-fetal needs
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE